| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2771 |
| Trial ID | NCT05020392 |
| Disease | Diffuse Large B-Cell Lymphoma | Chronic Lymphocytic Leukemia | Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Co-treatment | BTK inhibitor |
| Phase | Phase3 |
| Recruitment status | Recruiting |
| Title | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma |
| Year | 2021 |
| Country | China |
| Company sponsor | Wuhan Union Hospital, China |
| Other ID(s) | auto-CART-CD19 cells and BTKi |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||||
|
|||||||||||||